Articles On Botanix Pharmaceuticals (ASX:BOT)

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

New chief executive has experience executing clinical studies Dr Thurn was formerly part of the TGA’s Drug Safety Evaluation Branch Progress continues to be made on MND and canine cancer trials   PharmAust is strengthening its management...

PharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company reports he has extensive experience in drug discovery, regulation and clinical trials Dr Roger Aston will remain as Chair, but transition i...

Botanix Pharmaceuticals (ASX: BOT) has announced that its chief operating officer has been appointed as its chief executive officer.

Botanix Pharmaceuticals (BOT) appoints Dr Howie McKibbon as its newest CEO Dr McKibbon was previously Chief Operating Officer at the company He has more than 25 years of experience in the pharmaceutical industry and has led the launch...

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...

Local shares set to open sharply lower on Friday Wall Street tumbled by over 1pc overnight as tech momentum faded Betashares says buy ETF for AI exposure   The ASX is set to open much lower this morning as the momentum on US tech stocks d...

Mastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls a stunt at NSW Parliament   Here’s a quick snapshot of cannabis news making headlines over the past week: Mastercard has told banks to sto...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Botanix Pharmaceuticals (BOT) completes a $12.5 million placement and executes a buyout agreement for milestones and royalty payments for Sofpironium Bromide gel The company issues 104,166,667 new fully paid ordinary shares at 12 cents e...

Botanix Pharmaceuticals has secured commitments from investors to raise up to $12.5 million via an institutional placement to fund the buyout of financial obligations owed to another company.

Botanix Pharmaceuticals (BOT) raises $12.5 million through an institutional placement Funds will be used to extinguish future milestone and royalty payments related to Sofpironium Bromide The placement price of 12 cents per share repr...

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

OncoSil gets Ethics committee approval Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea   Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

A handful of ASX biotechs are entering their crucial stages of development Promising outlooks for PharmAxis, Botanix Pharma, and Paragon Care   Pharmaxis could surge if FDA application successful Broker Taylor Collison sees an Outperform...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has secured commitments to raise $10 million that will be used to progress its lead development program.

ASX 200 benchmark closes 0.5% higher, thanks to Energy surge.  XTX All Technology index has the batteries back in, up 1.26% for the day. Liontown farm-in huge news for E-I-E-I-Olympia Metals.   Local markets opened higher this morning (+0...

Botanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review The FDA detected no safety issues and no risk management issues or board requirements in the review of the Botanix product BOT says it wi...

Botanix Pharmaceuticals chief operating officer Dr Howie McKibbon believes Aussie Investors are comfortable backing early-stage, high-risk companies which is good for biotechs. When pitching an investment opportunity focused on a new drug...

The ASX 200 was unchanged  The ASX XEC slips 0.38% 8 out of 11 sectors were higher lead by Information Technology   The ASX 200 was unchanged today and the ASX XEC was down 0.38%.  The index has lost 0.98% for the last five days, but sit...

The co-founder of Botanix Pharmaceuticals says early interest from big industry players like Pfizer for the company’s gel aimed at treating excessive sweating was giving him confidence ahead of a key review. 

Tim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications.   After a rickety year dominated by the interest rate rises we...

Botanix Pharmaceuticals (BOT) receives confirmation from the US FDA that its new drug application (NDA) for its sofpironium bromide product is formally in reviewThe FDA confirms it identified no filing review issues in the company’s NDA, an...

Botanix Pharmaceuticals (BOT) has raised $5.96 million through a placement and share purchase plan (SPP)The company today reported its SPP, which closed last week, raised $960,000 — roughly a third of the $3 million soughtMeanwhile, the der...

Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-...

Botanix Pharmaceuticals (BOT) is raising up to $8 million through a private placement and a share purchase planBotanix received commitments from Antares Capital, a new institutional investor with knowledge of the company’s pipeline of asset...

Nuheara secures FDA over-the-counter approval for its new affordable hearing aid Nitro Software rejects unsolicited Potentia takeover bid ‘cos Alludo has a better one Edtech company Schrole nabs Rio Tinto deal to support its Simandou iron...

Aussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering some tent pegs into the dirt Thank the heavens, not much has changed since lunchtime   It’s not been a record-breaker by any stretch of the i...

Botanix Pharmaceuticals’ (BOT) Chief Commercial Officer (CCO) is promoted to Chief Operating Officer Dr Howie Mckibbon will retain his responsibilities as CCO but will expand his role to oversee manufacturing, medical affairs and regulatory...

Botanix Pharmaceuticals (BOT) receives positive data from its phase 1b/2 papulopustular rosacea clinical studyThe company reported positive results from the randomised, vehicle-controlled clinical study, which showed the 10 per cent dose re...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced what it describes as positive data from its BTX 1702 Phase 1b/2 papulopustular rosacea clinical study.

ASX 200 ends flat as Small caps s wee bit lower OLL investment sparks share price surge    We’re pretty flat on Wednesday. I am, the benchmark is and so is Australia as a nation and a continent. Luckily Gregor Stronach, my trusty fiend on...

It is hump day, which the ASX 200 benchmark celebrated with a series of increasingly erratic and – dare we say it, erotic – humps on its way to what looks like an unlikely 0.38% win. With another day in the bag, though, it’s time for an eve...

Clinical-stage dermatology Botanix Pharmaceuticals (ASX:BOT) has submitted a New Drug Application to the US FDA for the approval of sofpironium bromide for patients with severe primary axillary hyperhidrosis.

Botanix Pharmaceuticals (BOT) submits a new drug application (NDA) to the US FDA for the use of its sofpironium bromide gel for patients with severe primary axillary hyperhidrosisThe company says it is targeting FDA approval for the fourth...

Botanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to Japan Clinical dermatology company Botanix Pharma (ASX:BOT) has submitted a New Drug Application (NDA) to the US FDA for Sofpironium Bromi...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has closed the first tranche of its up to $7.5 million placement to new and existing institutional and sophisticated investors for the placement of up to 113,636,364 ful...

Botanix Pharmaceuticals (BOT) is tapping investors for $7.5 million via a share placementThe company will issue more than 113 million shares to private investors at 6.6 cents to raise the fundsBotanix says it will use the money to fund the...

Small caps burn rest of field. Again. Up 1.8% ASX 200 dips. Again DM1 jumps 75% over two sessions   The ASX Emerging Companies (XEC) index has climbed more than 1.8% higher on Wednesday while its erstwhile brethren which measures the favo...

Botanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitching investors for $5 million to take its Sofpironium Bromide product into sales in the United States. 

Botanix Pharmaceuticals (BOT) accelerates the submission of a New Drug Approval (NDA) for its Sofpironium Bromide gel to be ready to file in Q3 2022 To coincide with the acceleration, Botanix has ramped up its commercial launch activities...

Botanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx platform Cyclopharm’s Technegas is used ahead of competitor products in Covid-19 diagnosis Clinical dermatology company, Botanix Pharma (A...

Clinical dermatology company Botanix Pharmaceuticals (ASX: BOT) is preparing to submit a new drug application (NDA) for novel asset Sofpironium Bromide gel 15% for the treatment of excessive underarm sweating. The application will go to the...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced the timing of the submission of the NDA for Sofpironium Bromide has been accelerated.

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Botanix Pharmaceuticals (ASX: BOT) has provided the market with an update on its progress in transforming into a commercial-stage dermatology company following the acquisition of its latest asset, Sofpironium Bromide. The dermatology compan...